BRAINDTECH HAS DEVELOPED A SYSTEM OF EARLY DIAGNOSIS, PROGNOSIS AND MONITORING OF NEUROLOGICAL DISEASES BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. MICROVESICLES ARE PRODUCED ABOUT 10 YEARS BEFORE CLINICAL SYMPTOMS OF PATHOLOGY. BRAINDTECH IDENTIFIES PATHOLOGICAL-SPECIFIC PATTERNS OF MICRORNA CONTAINED IN MICROVESICLES, ISOLATED FROM LIQUID BIOPSIES. MICROVESICLES ARE CAPTURED USING A MICROFLUIDIC CHIP DEVELOPED BY IBM. BRAINDTECH HAS COVERED ITS INVENTIONS WITH TWO PATENTS, ONE RELATING TO THE METHOD FOR THE DIAGNOSIS, PROGNOSIS AND THERAPEUTIC MONITORING OF NEUROLOGICAL, NEURODEGENERATIVE AND INFLAMMATORY PATHOLOGIES, BASED ON THE ANALYSIS OF MICRORNA CONTAINED IN MICROVESICLES. THE SECOND RELATED TO THE IDENTIFICATION IN THE BLOOD OF SPECIFIC MICROGLIA MARKERS, AIMED AT ASSESSING DAMAGE TO BLOOD-BRAIN BARRIER FOR DIAGNOSTIC PURPOSES RELATED TO CRANIAL TRAUMA AND NEURODEGENERATIVE AND/OR NEUROIN PATHOLOGIES